EconomyEditor's PickNewsU.S. vaccine program head Slaoui expects Pfizer, Moderna vaccine data readouts in November-December

1 year ago125 min
https://topinvestingtoday.com/wp-content/uploads/2020/10/LYNXMPEG951ZN_L-mM6QAV.jpeg
imageStock Markets2 hours ago (Oct 06, 2020 04:10PM ET)

(C) Reuters. U.S. President Trump holds coronavirus response event in the Rose Garden at the White House in Washington

(Reuters) – The chief adviser for the U.S. government’s Operation Warp Speed COVID-19 vaccine program, Moncef Slaoui, on Tuesday said efficacy data readouts are expected from Pfizer Inc (NYSE:PFE) and Moderna (NASDAQ:MRNA) Inc between next month and December.

Speaking at a symposium conducted by the Johns Hopkins University and the University of Washington, Slaoui said data readouts from leading vaccine developers are expected to come in three waves over the next several months.

The first wave would be coming from Pfizer and Moderna, both of which are developing mRNA-based vaccines for the coronavirus, he said.

Slaoui said efficacy data on one or two vaccines will be available within the next month or two, for which there will be enough doses to immunize 30 million people between November and December.

Commenting on AstraZeneca (NYSE:AZN)’s vaccine program, Slaoui said while the company’s U.S. study remains on hold, data readouts on the vaccine’s effectiveness may be expected somewhere in late October or November from ongoing studies in the UK, Brazil and South Africa.

“At that time, we will have very few doses to be able to, if the decision was to approve the vaccine, immunize,” he said, adding that efforts are in place to scale up manufacturing and stockpiling of the vaccine.

U.S. vaccine program head Slaoui expects Pfizer, Moderna vaccine data readouts in November-December

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Leave a Reply

Your email address will not be published. Required fields are marked *